Loading clinical trials...
Loading clinical trials...
Evaluation of Efficacy in the Resolution of Post-Operative Inflammation and Pain in Patients Receiving Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery
This research will evaluate the efficacy of Omidria and Dexycu, Omidria and Dextenza, and Omidria and prednisolone acetate 1% in the resolution of post-operative inflammation and pain following cataract surgery.
Prospective, randomized trial where patients will be randomly assigned to 1 of 3 groups, each with a sample size of 25 (total n=75). Group 1 will receive DEXYCU + Omidria (Omidria = ketorolac + phenylephrine), group 2 will receive DEXTENZA + Omidria, and group 3 will receive prednisolone acetate + Omidria. Each of the drug combinations used in each of the 3 groups is standard of care, FDA approved, and will be used on label. 1:1:1, n=75 with 25 subjects assigned to each of the 3 groups.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Silverstein Eye Centers
Kansas City, Missouri, United States
Start Date
December 10, 2019
Primary Completion Date
December 23, 2020
Completion Date
December 23, 2020
Last Updated
June 15, 2023
15
ACTUAL participants
Omidria
DRUG
Dextenza (dexamethasone ophthalmic insert) 0.4mg
DRUG
Dexycu, 9% Intraocular Suspension
DRUG
Prednisolone Acetate 1%
DRUG
Lead Sponsor
Silverstein Eye Centers
Collaborators
NCT07362043
NCT07178639
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07154147